Naturex Revenues Up 28.7% in Q2
In the first half, revenues stood at EUR 48.1 millions, up 25.3% at USD constant rates. Proforma organic growth stood at 11.7%, perfectly in line with the group’s objectives.
08/07/08 Naturex had an excellent second quarter with revenues up 28.7% at constant USD rates (up 17.1% at current USD rates).
Over this period, proforma organic growth (including HP Botanicals, Chart Corporation and Berkem’s “Active Ingredients” division in 2007 and 2008) stood at 16.2% (up 5.8% at current USD rates) and sharply increased in comparison with the first quarter when it reached 7.3% at constant USD rates. This confirms the healthy expansion of the group in all sectors.
In the first half, revenues stood at EUR 48.1 millions, up 25.3% at USD constant rates (up 15.1% at constant USD rates). Proforma organic growth stood at 11.7% (up 2.5% at current USD rates), perfectly in line with the group’s objectives.
Encouraged by the development of all its business activities and the successful integration of its recent acquisitions (Chart Corporation and Berkem’s “Active Ingredients” division), Naturex confirms its objectives for the financial year: double-digit proforma organic growth at constant USD rates and a significant increase in operating margin that should reach 11% (8.4% in 2007).
Naturex, one of the main producers of rosemary extracts is particularly pleased with the decision of the European Food Safety Authority (EFSA) which paves the way for the official approval of rosemary extracts in the regulations on food additives, allowing them to be labelled as “antioxidant : rosemary extract”. Naturex considers that the future registration as a natural antioxidant will accelerate the increased use of rosemary extracts by the European food industry.
